Introduction
============

Bovine viral diarrhea viruses (BVDV) comprise two species within the *Pestivirus* genus that cause disease in ruminants. Producers worldwide experience financial loss due to BVDV infections ([@B13]; [@B25]). Animals with BVDV can exhibit several clinical signs including diarrhea, depression, and pyrexia ranging from clinically mild to severe; however, in many cases, signs of BVDV infections are subclinical and go undiagnosed or unnoticed ([@B13]; [@B21]; [@B25]; [@B30]). Regardless of clinical presentation, all BVDV infections result in significant loss of immune tissue, and it is theorized that the resulting immune suppression potentiates increased severity of subsequent infections ([@B28], [@B26]; [@B27]; [@B2]). Vaccine combinations are available to limit transmission and clinical disease, but not necessarily prevent BVDV infections ([@B11]; [@B25]; [@B30]). Identifying animals that may have damaged immune systems and that are at risk to develop respiratory disease could improve herd health management.

Before the identification and characterization of lin-4 in 1993, research on microRNAs was non-existent ([@B29]). MicroRNAs, are small (21--25 nucleotides) single-stranded non-coding RNAs that have been shown to regulate gene expression post-transcriptionally ([@B29]; [@B9]; [@B18]; [@B15]). They have been associated with many biological processes including development, innate immunity, adaptive immune response, and disease ([@B29]; [@B18]; [@B20]; [@B12]; [@B5]; [@B6]; [@B4]).

Studies that identify microRNAs associated with cattle acutely infected with BVDV are non-existent. The type of tissue utilized in such a study should be applicable to the study's objective. The objective of this study was to identify microRNAs found in the serum of colostrum deprived Holstein calves that are associated with infection from a non-cytopathic field strain of BVDV of typical virulence ([@B21]). Results from this study will create knowledge of dysregulated microRNAs to possibly identify biomarkers of a BVDV infection. Ideally, the sampled tissue should be able to be collected with minimal harm to the animal. Sera was utilized in the current study.

Materials and Methods {#s1}
=====================

The animals used in this study represented positive and control groups within two larger studies. Animals were housed and cared for according to the management protocol approved by the Animal Care and Use Committee of the National Animal Disease Center in Ames, IA, United States (ARS-2667).

Virus Characterization and Propagation
--------------------------------------

The BVDV2 strain used in these studies, BVDV2-RS886, was first isolated from a persistently infected calf ([@B21]). Under controlled conditions, infection of colostrum deprived calves with this virus strain results in a low-grade pyrexia and leukopenia, or a reduction in circulating immune cells ([@B24]). Virus was propagated and inoculum prepared as described previously ([@B24]).

Animals
-------

In two replicate studies a total of nine colostrum deprived male Holstein calves between 3 and 5 weeks of age were assigned to either a control or challenge group. In both replicates of the study, calves in the control group (*n* = 4) were mock-inoculated on day 0 with lysed cell culture supernatant from non-infected Madin Darby bovine kidney (MDBK) cells. Calves in the BVDV challenge group (*n* = 5) were exposed to a non-cytopathic field strain of BVDV (BVDV2-RS886) on day 0. Inoculations consisted of 4 mL of viral preparation (1 × 10^6^ TCID/mL) or clarified freeze/thaw lysate of MDBK cells and was delivered by the nasal route using either an intranasal atomization (LMA MAD300 Nasal atomizer, Teleflex, Inc., Research Triangle Park, NC, United States) or by placing directly in the nose.

Following inoculation calves were observed twice daily for signs of respiratory disease. Fresh serum samples were collected at four different times; (1) a baseline measurement (day 0); collected prior to the initial inoculation; (2) 4 days post-initial inoculation; (3) 9 days post-initial inoculation; and (4) 16 days post-initial inoculation. Serum samples were collected from all nine calves at all four times via jugular venipuncture in SST vacutainer tubes (BD, Franklin Lakes, NJ, United States). The vacutainer tubes were incubated at 37°C for 30 min. and were centrifuged at 1250 × *g* for 30 min. The isolated serum samples were placed into 2 mL vials and were stored at -80°C until processed.

MicroRNA Isolation
------------------

Purification of total RNA from the serum samples was completed using the miRNeasy Serum/Plasma Kit (QIAGEN, Germantown, MD, United States). The RNA was extracted according to manufacturer's instructions, and the samples were eluted in 14 μL RNase-free water. After extraction, the concentration of microRNAs extracted in each sample was determined using a 10--40 nucleotide gate on an Agilent 2100 Bioanalyzer Small RNA chip (Agilent Technologies, Santa Clara, CA, United States).

Library Preparation and Sequencing
----------------------------------

Libraries were prepared using the NEBNext Multiplex Small RNA Library Prep Set for Illumina Set 1 and 2 (New England BioLabs, Ipswich, MA, United States). Six microliters (6 μL) of each extracted serum sample was individually indexed with one of the Illumina 1-23 indexed primers. Library PCR products were then purified to single- and double-stranded DNA fragments and concentrated to 35 μL using the QIAquick PCR purification kit (QIAGEN, Germantown, MD, United States). The quality and quantity of each library was determined using a 135--170 nucleotide gate on an Agilent 2100 Bioanalyzer High Sensitivity DNA chip (Agilent Technologies, Santa Clara, CA, United States). A total of 30 ng of each library was pooled into one of two pools. Twenty-three total libraries in each pool were created and size selected (142--170 nt) according to manufacturer's instructions using the Pippin Prep on a 3% Agarose gel without Ethidium Bromide (SAGE Sciences, Beverly, MA, United States). After the gel was run, the pools were concentrated using the QIAquick PCR purification kit (QIAGEN, Germantown, MD, United States) by eluting in 32 μL of RNase-free water. The concentration of each pool was determined using a 135--170 nucleotide gate on an Agilent 2100 Bioanalyzer High Sensitivity DNA chip (Agilent Technologies, Santa Clara, CA, United States). The pool was stored at -20°C until sequencing. Each pool was sequenced by 50 cycles on the Illumina HiSeq 2500 System (Illumina, San Diego, CA, United States).

Data and Statistical Analysis
-----------------------------

The Illumina sequences were inspected for quality using FastQC v0.11.2^[1](#fn01){ref-type="fn"}^, and the adapter was removed using the fastx_clipper program in a fastx toolkit^[2](#fn02){ref-type="fn"}^. Sequences of bovine microRNAs and their precursors were downloaded from miRBase (v21^[3](#fn03){ref-type="fn"}^). Reads were mapped to known bovine microRNAs, and read counts for each microRNA were compiled and normalized using miRDeep2 ([@B10]). In order to obtain minimum statistical power, analysis was completed on microRNAs with \>1,000 total reads ([@B31]; [@B22]). Sequences are available on the NCBI SRA under BioProject accession [SRP091488](SRP091488).

Statistical analysis was completed using the Mixed procedure of SAS (SAS, Inst. Inc., Cary, NC, United States). The model included the main effects of treatment (challenge or control groups), time (days 0, 4, 9, and 16), and the interaction between treatment and time. Day 0 read counts were included in the model as a covariate, the replicate of the study (1 or 2) was included as a random effect, and animal ID was included as a repeated measure. The study was designed to ascertain nominal significant differences with the minimal number of animals; therefore, un-corrected significances are presented. Significances should be taken in consideration when interpreting results.

Results
=======

At day 3 all BVDV challenged animals started to develop fever and lymphopenia. The fevers resolved by day 7 and lymphocyte counts started to increase by day 9; however, lymphocyte counts remained higher than pre-challenge levels at day 16. Control animals showed no signs of fever or lymphopenia.

A total of 191,071,075 reads were obtained from sequencing, and 905,861 reads mapped to bovine microRNAs. Four hundred twenty-seven different microRNAs were identified with at least one read among all animals. Of which, 288 microRNAs had \<100 total reads and 77 microRNAs had between 100 and 1,000 total reads. Sixty-two microRNAs had greater than 1,000 total reads.

Those 62 microRNAs were further analyzed (Supplementary Table [1](#SM1){ref-type="supplementary-material"}). Mean counts between BVDV challenged and control animals were similar for all 62 microRNAs (*P* \> 0.05).

Seven microRNAs were significantly different across time, regardless of treatment group. **Table [1](#T1){ref-type="table"}** shows the normalized mean read counts across all animals, regardless of treatment, for each significant microRNA across time. Between day 0 and day 4, two microRNAs increased in number of reads, two decreased, and three remained statistically constant during this period. Between day 4 and day 9, three microRNAs increased in number of reads, while four remained constant. Between day 9 and day 16, six microRNAs decreased in number of reads, and only bta-miR-185 remained constant during this period.

###### 

MicroRNA, normalized mean in reads per million (RPM) for each response time, standard error (SE), and their association (*P*-value) across all animals.

                   Response time point                                                     
  ---------------- --------------------- ------------- ------------ ------------- -------- -------
  Bta-miR-339a     902^a^                1,526^a^      2,504^b^     800^a^        319      0.003
  Bta-let-7c       1,952^a^              908^b^        1,498^a^     887^b^        202      0.002
  Bta-miR-486      40,417^a,c^           86,065^a,b^   103,779^b^   35,799^c^     17,744   0.01
  Bta-miR-2284x    2,208^a^              1,421^b^      2,113^a^     1,542^b^      165      0.02
  Bta-miR-30e-5p   1,462^a^              2,972^b^      2,901^b^     2,781^b^      476      0.02
  Bta-miR-185      683^a^                1,233^a,b^    1,583^a^     633^b^        357      0.03
  Bta-miR-92a      24,695^a^             40,525^b,c^   46,815^b^    28,725^a,c^   7,079    0.03

1

Day 0 samples were collected 1--2 days prior to challenge.

a,b,c

Means (RPM) without a common superscript within row are statistically different (

P

≤ 0.05).

Bta-miR-423-5p (*P* = 0.008) differed in number of reads between BVDV challenged and control animals across time. The number of reads for bta-miR-423-5p in BVDV challenged animals peaked above day 0 levels by day 4 then decreased over time while the number of reads in control animals tended to decrease throughout the study (**Figure [1](#F1){ref-type="fig"}**). Significant differences between BVDV challenged and control animals at individual time points were undetected, however, levels of bta-miR-423-5p in both BVDV challenged and control groups returned to day 0 levels by day 16.

![Interaction of time and challenge status for bta-miR-423-5p (*P* = 0.008). ^∗^RPM stands for reads per million. Dashed line corresponds to cattle challenged with bovine viral diarrhea virus (BVDV). Solid line corresponds to control animals.](fgene-08-00091-g001){#F1}

Bta-miR-151-3p (*P* = 0.005) also differed in number of reads between BVDV challenged and control animals across time. The number of reads for bta-miR-151-3p in BVDV challenged animals peaked above day 0 levels by day 9 and returned to day 0 levels by day 16 (**Figure [2](#F2){ref-type="fig"}**). In control animals, the number of reads for bta-miR-151-3p steadily decreased across time, resulting in significantly lower levels from day 0 levels by day 16 (*P* = 0.007). Nine days after being challenged, BVDV challenged animals had a significantly greater number of reads of bta-miR-151-3p than control animals (*P* = 0.006).

![Interaction of time and challenge status for bta-miR-151-3p (*P* = 0.005). ^∗^RPM stands for reads per million. Dashed line corresponds to cattle challenged with BVDV. Solid line corresponds to control animals. An asterisk above a time point represents a significant (*P* \< 0.05) difference in number of read counts between BVDV challenged and control animals at that particular time point.](fgene-08-00091-g002){#F2}

Discussion
==========

MiR-151-3p was shown to be significantly lower in cells that were infected with *Brucella melitensis* ([@B32]). *B. melitensis* replicates within host cells while remaining undetected from the host immune system ([@B32]; [@B16]). Some studies indicate that host microRNA expression can be regulated by pathogens ([@B3]; [@B8], [@B7]; [@B32]). Unlike *B. melitensis*, BVDV does not avoid a host immune response to survive. Potentially then, *B. melitensis* infected cells express a lower level of miR-151-3p in order to avoid a host immune response, while BVDV, which does elicit a host immune response, showed an increase in miR-151-3p, particularly 9 days after infection. The differences in expression of miR-151-3p between *Brucella melitensis* and BVDV infection could be due to the differences in the way the pathogens replicate in the host.

MiR-423-5p has been identified in humans and cattle with disease and viral or bacterial infections ([@B17]; [@B1]; [@B14]; [@B19]; [@B23]). An increase of miR-423-5p was observed in humans that had myasthenia gravis, pulmonary fibrosis, or were infected with a polyomavirus, which is a non-enveloped DNA virus ([@B17]; [@B1]; [@B23]). In cattle, a similar up-regulation of miR-423-5p was seen in mammary glands exposed to *Streptococcus uberis* or *Escherichia coli* ([@B14]; [@B19]). This study observed an increase of bta-miR-423-5p in BVDV challenged animals 4 days post-viral challenge. Additionally, bta-miR-423-5p in BVDV challenged animals tended to have a higher number of reads than control animals from day 4 through 16. Another study identified bta-miR-423-5p to be down-regulated in cattle exposed to *Mycoplasma bovis* vs. non-exposed cattle ([@B4]). It is possible that bta-miR-423-5p continues to decrease in levels after day 16, falling below the number of reads in control animals. The mature steers from [@B4] study may have been exposed to *M. bovis* greater than 16 days prior to serum collection, supporting the lower expression levels of bta-miR-423-5p in positive animals.

Further research is needed to identify potential biomarkers to indicate timing of BVDV exposure in cattle. In this study, the most dramatic difference in number of reads between BVDV challenged and control animals was 9 days after BVDV exposure for both bta-miR-423-5p and bta-miR-151-3p. Four days after BVDV exposure, bta-miR-423-5p increased, with the number of reads higher than control animals, and bta-miR-151-3p remained similar to the control animals until day 9. Bta-miR-423-5p decreased in number of reads to become similar to control animals, while bta-miR-151-3p continued to have a higher number of reads in BVDV challenged animals than control animals on day 16. If bta-miR-423-5p or bta-miR-151-3p was to be used as a "BVDV timing" biomarker, results from this study suggest that serum collected 9 days post-BVDV challenge would be the most beneficial in order to differ between BVDV challenged and unchallenged animals. However, 9 day post-challenge, or infection may not be the most valuable time to identify the onset of respiratory disease.

Respiratory disease caused by BVDV results in an estimated \$10-40 million loss per million calvings nationally ([@B13]). The clinical signs of cattle exposed to BVDV are diverse and most times undetectable, leading to difficulties in diagnoses or proper treatment ([@B11]; [@B21]; [@B30]). Once an animal is infected with BVDV, it is immune compromised, making the animal more at risk to develop respiratory disease. This study was conducted to identify potential microRNAs that could act as biomarkers indicating the timing of BVDV exposure to cattle. While there weren't any microRNAs identified in this study that could be used as specific biomarkers of BVDV infection vs. non-infected cattle post-exposure, there were two microRNAs that could potentially be used as a biomarkers to indicate the timing of BVDV exposure.
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